Gujarat Themis Biosyn Limited has signed an Asset Purchase Agreement with Sanofi, French holding Company of the Sanofi group headquartered in Paris, for acquiring a portfolio of anti-tuberculosis (TB) and anti-infective brands along with associated trademark rights. The disclosure was made to BSE Limited and National Stock Exchange of India Limited on April 23, 2026, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Acquisition Overview

The transaction involves the acquisition of 13 established branded generic products with a strong presence across more than 55 countries in Europe, the Middle East and Africa. The portfolio focuses on tuberculosis and anti-infectives segment with key molecules including Rifampicin, Rifapentine, and Levofloxacin. The consideration for the transaction is Euro 158 million payable in cash at closing.

Financial Performance

The concerned portfolio reported net sales of approximately Euro 62 million for the year ended 2025. Revenues from the 13 established branded generic products in the last 3 years were FY23 - Euro 66 million, FY24 - Euro 67 million, and FY25 - Euro 62 million.

Strategic Value and Integration

This Asset Purchase represents a significant step in GTBL's strategy to strengthen its global generic pharmaceuticals platform and expand its presence in the anti-infective segment. The transaction would provide immediate access to regulated and semi-regulated markets, enabling GTBL to enhance its international footprint. It would also create a strong opportunity for forward integration, allowing the company to leverage its existing capabilities in fermentation-based intermediates and APIs to support the acquired finished dosage formulations portfolio and drive improved realizations across the value chain.

Transaction Structure and Timeline

The acquisition includes marketing authorizations, brands, regulatory dossiers and inventory and associated commercial rights. The transaction does not involve the acquisition of any legal entity, manufacturing facilities or employees, making it a capital-efficient and asset-light expansion. The transaction is subject to obtaining antitrust and foreign direct investment approvals in applicable jurisdictions and is expected to be closed by the end of December 2026.

Gujarat Themis Biosyn Limited has successfully concluded its postal ballot process, with shareholders approving key corporate governance resolutions through electronic voting. The company announced the voting results on April 20, 2026, following the completion of the e-voting period that ran from March 19 to April 17, 2026.

Director Re-appointment Receives Overwhelming Support

The first resolution concerning the re-appointment of Mrs. Kirandeep Madan (DIN: 00686547) as Non-Executive Woman Independent Director received exceptional shareholder support. This special resolution was passed with an overwhelming majority, demonstrating strong confidence in the proposed appointment.

Related Party Transaction Approval

The second resolution, an ordinary resolution for approval of material related party transactions with Themis Medicare Limited (TML), also secured shareholder approval, though with a narrower margin. The resolution passed with 52.5598% votes in favor.

Notably, the promoter and promoter group abstained from voting on this resolution due to their interest in the agenda, with 169770 votes declared invalid from this category.

E-voting Process and Compliance

The postal ballot was conducted in compliance with Section 108 and 110 of the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. CS Ketan Ravindra Shirwadkar of KRS AND CO. served as the scrutinizer for the process.

Key process details include:

• Cut-off Date: Friday, March 13, 2026
• Notice Dispatch: Wednesday, March 18, 2026
• E-voting Period: March 19, 2026 (9:00 AM) to April 17, 2026 (5:00 PM)
• Platform: CDSL's evotingindia.com
• Advertisement: Published in Western Times (English and Gujarati editions) on March 19, 2026

Shareholder Participation

The voting saw significant participation across different shareholder categories. Out of total outstanding shares of 108965265, a total of 79333821 votes were polled for the first resolution, representing 72.8065% of outstanding shares. For the second resolution, 2652014 votes were polled, representing 2.4338% of outstanding shares.

The company has made the voting results and scrutinizer's report available on its website at www.gtbl.in , ensuring transparency and compliance with regulatory requirements. The successful completion of the postal ballot process reinforces the company's commitment to good corporate governance practices.